Development of monitoring biomarker signatures in Duchenne muscular dystrophy

被引：0
|
作者：
De Vries, S. [1 ]
Degan, C. [1 ]
Tobin, R. [2 ]
Jimenez-Requena, A. [3 ]
Ajeenah, A. [3 ]
Johansson, C. [3 ]
Van der Burgt, Y. [1 ]
Diaz-Manera, J. [4 ]
Guglieri, M. [4 ]
Szigyarto, C. Al-Khalili [3 ]
Spitali, P. [1 ]
Hathout, Y. [5 ]
Tsonaka, R. [1 ]
Dang, U. [2 ]
机构：
[1] Leiden Univ, Med Ctr, Leiden, Netherlands
[2] Carleton Univ, Ottawa, ON, Canada
[3] KTH Royal Inst Technol, Stockholm, Sweden
[4] Newcastle Univ, Newcastle, England
[5] SUNY Binghamton, Binghamton, NY USA
来源：
NEUROMUSCULAR DISORDERS | 2024年 / 43卷
关键词：
D O I：
10.1016/j.nmd.2024.07.500
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
296P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Chronodisruption as a biomarker in Duchenne muscular dystrophy
    Alexander, M.
    Monreal-Gutierrez, M.
    Reid, A.
    English, K.
    Wolff, C.
    Lopez, M.
    Siegel, B.
    Phan, H.
    Gamble, K.
    Esser, K.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S149 - S149
  • [2] Fibronectin is a serum biomarker for Duchenne muscular dystrophy
    Martin, F. Cynthia
    Hiller, Monika
    Spitali, Pietro
    Oonk, Stijn
    Dalebout, Hans
    Palmblad, Magnus
    Chaouch, Amina
    Guglieri, Michela
    Straub, Volker
    Lochmueller, Hanns
    Niks, Erik H.
    Verschuuren, Jan J. G. M.
    Aartsma-Rus, Annemieke
    Deelder, Andre M.
    van der Burgt, Yuri E. M.
    't Hoen, Peter A. C.
    PROTEOMICS CLINICAL APPLICATIONS, 2014, 8 (3-4) : 269 - 278
  • [3] Biomarker development to support the clinical development of utrophin modulators for Duchenne muscular dystrophy therapy
    Tinsley, J.
    Janghra, N.
    Wilson, F.
    Sewry, C.
    Horne, G.
    Morgan, J.
    NEUROMUSCULAR DISORDERS, 2014, 24 (9-10) : 826 - 826
  • [4] Biomarker development to support the clinical development of utrophin modulators for Duchenne muscular dystrophy therapy
    Tinsley, J.
    Janghra, N.
    Morgan, J.
    Sewry, C.
    Muntoni, E.
    Elsey, D.
    Wilson, F.
    Davies, K.
    NEUROMUSCULAR DISORDERS, 2015, 25 : S251 - S251
  • [5] Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy
    Mariot, Virginie
    Le Guiner, Caroline
    Barthelemy, Ines
    Montus, Marie
    Blot, Stephane
    Torelli, Silvia
    Morgan, Jennifer
    Muntoni, Francesco
    Voit, Thomas
    Dumonceaux, Julie
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2020, 18 : 415 - 421
  • [6] Biomarker panel for Duchenne muscular dystrophy clinical trials
    Tsioutsias, I.
    Bautista, A.
    Terrill, J.
    Bakker, A.
    Pinniger, G.
    Arthur, P.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [7] Urine titin as a novel biomarker for Duchenne muscular dystrophy
    Ishii, M.
    Nakashima, M.
    Kamiguchi, H.
    Zach, N.
    Kuboki, R.
    Baba, R.
    Hirakawa, T.
    Suzuki, K.
    Quinton, M.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S66 - S66
  • [8] Urine titin as a novel biomarker for Duchenne muscular dystrophy
    Ishii, Misawa Niki
    Nakashima, Masato
    Kamiguchi, Hidenori
    Zach, Neta
    Kuboki, Ryosuke
    Baba, Rina
    Hirakawa, Takeshi
    Suzuki, Kazunori
    Quinton, Maria
    NEUROMUSCULAR DISORDERS, 2023, 33 (04) : 302 - 308
  • [9] Biomarker Potential of Extracellular miRNAs in Duchenne Muscular Dystrophy
    Coenen-Stass, Anna M. L.
    Wood, Matthew J. A.
    Roberts, Thomas C.
    TRENDS IN MOLECULAR MEDICINE, 2017, 23 (11) : 989 - 1001
  • [10] Drug development of vamorolone for Duchenne muscular dystrophy
    Clemens, P.
    Guglieri, M.
    Morgenroth, L.
    Damsker, J.
    Smith, A.
    Hathout, Y.
    Cnaan, A.
    Smith, E.
    Mah, J.
    Byrne, B.
    Castro, D.
    Finkel, R.
    Kuntz, N.
    McDonald, C.
    Nevo, Y.
    Ryan, M.
    Tulinius, M.
    Webster, R.
    Hoffman, E.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S217 - S218
12345